Research

A Quality Opportunity

The premium for top-tier ASX companies hits a historic low at an opportune time.

Like any other asset, shares in the highest quality Australian companies typically carry a valuation premium to those at the lower end of the scale. Under certain market conditions, this premium can be substantial.

Investors then have to choose between paying significantly higher multiples for quality companies with strong balance sheets and consistent financial performance, or pay lower multiples for companies who don’t have the same reputation or track record.

At the moment, however, the spread between the highest quality companies and those outside the criteria is no longer as wide as it was a year ago. The ASX's highest quality stocks currently trade around 18 times forward price-earnings, while those at the lower end of the quality scale trade at 16.6 times forward price-earnings.

This gap of just 1.4 is not only well below the five-year moving average, it’s the lowest it has been since the market crisis of 2008. If quality stocks are market weighted, giving large-cap stocks a greater proportion in the analysis, the spread is even smaller. As a result, you can buy into Australia’s higher quality companies at a significant discount to the norm.

Relative Value Z-Score, 1988-2017, Forward PE, PB and Div Yield

Sources: FactSet, Morgan Stanley Research

Measuring Quality

While ‘quality’ has a variety of definitions, the most common include measures such as fundamental profitability, effective use of capital, strong balance sheets and relatively low volatility. The Morgan Stanley Global (ex-US) Quant framework calculates a Quality score based on an equally-weighted combination of 14 measures of financial and market performance. The highest-ranking 25% of stocks on the ASX, by these measures, were designated as quality companies for the purpose of the study.

Why Quality Companies Have Underperformed

So what are the market dynamics that have led to the shrinking gap in values? The Morgan Stanley Australian quant team, led by Steven Ye, believes that the phenomenon is largely the result of the reflation trade that has been prevalent over the past year. Driven by the belief that a recovering global economy and economic policies of the new American administration may ignite inflation, Australian portfolio managers rotated into stocks with higher earnings multiples in search of upside potential. This drove a rare year of outperformance of lower quality over higher quality stocks on the ASX.

A Timely Opportunity

Morgan Stanley’s analysts believe, however, that the reflation trade has largely run its course. This is primarily due to delays in implementing the inflationary agenda of the new US administration as well as disappointing recent retail sales figures and some contraction in the core consumer price index. They conclude that the cycle may be turning, creating a potential buying opportunity for the highest quality stocks.

While there is no particularly bad time to buy into quality companies trading at a compressed premium, the present may prove to be a particularly opportune moment. According to the Morgan Stanley Research Macro + Quant report ‘Should We Be Buying Some Quality’, market sentiment remains elevated and at risk of disappointment. While the analysts believe that underlying macro trends are positive on a global basis, domestic conditions show signs of weakness.

Higher risk conditions tend to favour higher quality stocks. Historically, these high-quality companies tend to outperform those in the bottom 25% of the rankings when interest rates are rising and equity prices are softening. These stronger companies are seen to be more resilient and benefit from a ‘flight to quality’. Lower quality companies, conversely, trade at lower multiples as their greater perceived risk demands a discount.

With domestic risks increasing and quality companies at relatively attractive prices, now might be a good time to re-examine your portfolio in order to ensure it is appropriately positioned. This convergence of valuations is a relatively unique occurrence that may present a significant investment opportunity.

Cumulative Total Return Index: 100 = Jan 1988, Market Cap Weighted Return

Sources: FactSet, Morgan Stanley Research

For more information on the Morgan Stanley Research Macro + Quant report or to discuss how the dynamics discussed in this article might apply to your investment planning, please speak with your Morgan Stanley financial adviser.

  • Important Information

    All material on this website has been prepared by one or all of Morgan Stanley Australia Limited (ABN 67 003 734 576, AFSL 233742), Morgan Stanley Australia Securities Limited (ABN 55 078 652 276, AFSL 233741), a participant of the ASX Group and Chi-X Australia, Morgan Stanley Investment Management (Australia) Pty Limited (ABN 22 122 040 037, AFSL 314182) and/or Morgan Stanley Wealth Management Australia Pty Ltd. (ABN 19 009 145 555, AFSL 240813), a participant of the ASX Group (collectively “Morgan Stanley”), for informational purposes only and is not a solicitation of any offer to buy or sell any security or other financial instrument or to participate in any trading strategy. Unless otherwise stated, the material was not prepared by the Morgan Stanley Research Department and is not a research report as defined under ASIC guidance.

    This communication provides market commentary and strategy ideas to clients of Morgan Stanley and its affiliates. Such commentary and ideas are based upon generally available information. Although the information has been obtained from sources believed to be reliable, we do not guarantee its accuracy, and such information may be incomplete or condensed. All opinions and estimates included in this document constitute our judgment as of this date and are subject to change without notice.

    The material on this website contains factual information only and is not intended to reflect any recommendations or financial advice, nor is it an offer or solicitation in relation to any particular financial product. To the extent this document does contain any general advice, it has been prepared without taking into account your objectives, financial situation or needs, and because of this, you should, before acting on it, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs, and if the advice relates to the acquisition of a particular financial product for which an offer document (such as a prospectus or product disclosure document) is available, you should obtain the offer document relating to the particular product and consider it before making any decision whether to acquire the product.